Innate Pharma
IPHA
9 hedge funds and large institutions have $1.13M invested in Innate Pharma in 2023 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 2 closing their positions.
0% less ownership
Funds ownership: 0.5% → 0.5% (-0%)
18% less funds holding
Funds holding: 11 → 9 (-2)
24% less capital invested
Capital invested by funds: $1.49M → $1.13M (-$363K)
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Optiver Holding
Amsterdam,
Netherlands
|
+$381K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$3.58K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$350K |
| 2 |
Millennium Management
New York
|
-$31.4K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$11K |
| 4 |
Morgan Stanley
New York
|
-$2.07K |
| 5 |
Citigroup
New York
|
-$201 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Optiver Holding
Amsterdam,
Netherlands
| $636K | +$381K | +118,563 | +112% |
|
|
2
Millennium Management
New York
| $176K | -$31.4K | -9,785 | -14% |
|
|
3
Morgan Stanley
New York
| $139K | -$2.07K | -645 | -1% |
|
|
4
Bank of America
Charlotte,
North Carolina
| $133K | -$350K | -109,042 | -70% |
|
5
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $37.8K | – | – | – |
|
|
6
UBS Group
Zurich,
Switzerland
| $3.59K | +$3.58K | +1,113 | +762% |
|
|
SPIA
7
Steward Partners Investment Advisory
New York
| $1.43K | – | – | – |
|
8
Barclays
London,
United Kingdom
| $1.17K | – | – | – |
|
|
TRCT
9
Tower Research Capital (TRC)
New York
| – | -$11K | -2,954 | Closed |
|
|
10
Citigroup
New York
| – | -$201 | -54 | Closed |
|
11
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$3 | -1 | -0.8% |
|
IPHA Hedge Fund Activity: Q1 2023 in Review
9 of the 6,277 institutional investors tracked by Wall St. Rank reported a position in Innate Pharma (IPHA) for Q1 2023, worth a combined $1.13M — down 24% from $1.49M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of IPHA and 0 opened new positions — a net loss of 2 holders — while 4 trimmed existing stakes and 2 added.
The largest buyer was Optiver Holding, adding an estimated $381K. The largest seller was Bank of America, cutting an estimated $350K.
- 9 institutional investors held Innate Pharma (IPHA) as of Q1 2023, down from 11 in Q4 2022.
- Funds reported $1.13M of Innate Pharma stock for Q1 2023, down 24% quarter-over-quarter.
- 0 funds opened new Innate Pharma positions in Q1 2023 and 2 closed out, a net change of -2 holders.
- The largest Innate Pharma buyer in Q1 2023 was Optiver Holding, an estimated $381K added.
- The largest Innate Pharma seller in Q1 2023 was Bank of America, an estimated $350K sold.
Based on aggregated 13F filings for Q1 2023.